Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLS009 Single Agent and in Combination With Venetoclax and Azacitidine in Hematologic Malignancies
NCT04588922Phase 2Recruiting
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of GFH009 in acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoma, sponsored by SELLAS Life Sciences Group, Inc.. Started May 2021; status: recruiting.
02
Drugs
GFH009
03
Conditions
acute myeloid leukemia (AML)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)lymphoma
Beyond the preview
Go deeper on NCT04588922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588922.